The Microbiome and Psoriatic Arthritis

  • Hester Eppinga
  • Sergey R. Konstantinov
  • Maikel P. Peppelenbosch
  • H. Bing Thio
PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)
Part of the following topical collections:
  1. Topical Collection on Psoriatic Arthritis

Abstract

Psoriatic arthritis is a chronic inflammatory joint disease, seen in combination with the chronic inflammatory skin disease psoriasis and belonging to the family of spondylarthritides (SpA). A link is recognized between psoriatic arthritis and inflammatory bowel disease (IBD). Environmental factors seem to induce inflammatory disease in individuals with underlying genetic susceptibility. The microbiome is a subject of increasing interest in the etiology of these inflammatory immune-mediated diseases. The intestinal microbiome is able to affect extra-intestinal distant sites, including the joints, through immunomodulation. At this point, evidence regarding a relationship between the microbiome and psoriatic arthritis is scarce. However, we hypothesize that common immune-mediated inflammatory pathways seen in the “skin–joint–gut axis” in psoriatic arthritis are induced or at least mediated by the microbiome. Th17 has a crucial function in this mechanism. Further establishment of this connection may lead to novel therapeutic approaches for psoriatic arthritis.

Keywords

Microbiome Microbiota Mycobiome Psoriatic arthritis Psoriasis Spondyloarthritis Autoimmunity 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Hester Eppinga, Sergey R. Konstantinov, Maikel P. Peppelenbosch, and H. Bing Thio declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36(2):361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2005;17(4):406–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Konstantinov SR, van der Woude CJ, Peppelenbosch MP. Do pregnancy-related changes in the microbiome stimulate innate immunity? Trends Mol Med. 2013;19(8):454–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol. 2012;2:104.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9(10):577–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17(3):323–33.PubMedGoogle Scholar
  8. 8.
    Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti-Infect Ther. 2010;8(4):435–54.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013;15(3):314. 012-0314-y.PubMedCrossRefGoogle Scholar
  11. 11.
    Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759–95.PubMedCrossRefGoogle Scholar
  13. 13.
    de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev. 2012;70 Suppl 1:S45–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60(5):631–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.PubMedCrossRefGoogle Scholar
  16. 16.
    Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Kempsell KE, Cox CJ, Hurle M, Wong A, Wilkie S, Zanders ED, et al. Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect Immun. 2000;68(10):6012–26.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Stebbings S, Jenks K, Roberts R, Schultz M. The immune response to gut bacteria in spondyloarthritis: a role in pathogenesis? JCRMM. 2010;1:1–10.Google Scholar
  21. 21.
    Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012;336(6086):1314–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010;6(1):e1000713.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Iliev ID, Underhill DM. Striking a balance: fungal commensalism versus pathogenesis. Curr Opin Microbiol. 2013;16(3):366–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ott SJ, Kuhbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, et al. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol. 2008;43(7):831–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Mason KL, Erb Downward JR, Falkowski NR, Young VB, Kao JY, Huffnagle GB. Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis. Infect Immun. 2012;80(1):150–8.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Naglik JR, Fidel Jr PL, Odds FC. Animal models of mucosal Candida infection. FEMS Microbiol Lett. 2008;283(2):129–39.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64(12):5225–32.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, Lagadec P, et al. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One. 2010;5(1):e8925.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1083–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496–508.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10(10):717–25.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Fung I, Garrett JP, Shahane A, Kwan M. Do bugs control our fate? The influence of the microbiome on autoimmunity. Curr Allergy Asthma Rep. 2012;12(6):511–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12(5):599–606.PubMedCrossRefGoogle Scholar
  37. 37.
    Curran SA, FitzGerald OM, Costello PJ, Selby JM, Kane DJ, Bresnihan B, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol. 2004;172(3):1935–44.PubMedGoogle Scholar
  38. 38.
    Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001;166(4):2878–86.PubMedGoogle Scholar
  39. 39.
    Choy E. T cells in psoriatic arthritis. Curr Rheumatol Rep. 2007;9(6):437–41.PubMedCrossRefGoogle Scholar
  40. 40.•
    Hormannsperger G, Clavel T, Haller D. Gut matters: microbe-host interactions in allergic diseases. J Allergy Clin Immunol. 2012;129(6):1452–9. The authors established the importance of microbe–host interaction in the development of immune-mediated disorders.PubMedCrossRefGoogle Scholar
  41. 41.
    Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–27.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578–93.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008;38(10):2636–49.PubMedCrossRefGoogle Scholar
  44. 44.
    Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med. 2012;18(12):1750–1.PubMedCrossRefGoogle Scholar
  45. 45.
    Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–29.PubMedCrossRefGoogle Scholar
  46. 46.
    Benham H, Norris P, Goodall J, Wechalekar MD, Fitzgerald O, Szentpetery A, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15(5):R136.PubMedCrossRefGoogle Scholar
  47. 47.
    Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:12–29.PubMedCrossRefGoogle Scholar
  48. 48.
    Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Ding HS, Yang J, Yang J, Ding JW, Chen P, Zhu P. Interleukin-17 contributes to cardiovascular diseases. Mol Biol Rep. 2012;39(7):7473–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Ritchlin CT. From skin to bone: translational perspectives on psoriatic disease. J Rheumatol. 2008;35(7):1434–7.PubMedGoogle Scholar
  51. 51.
    Yamamoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21(5):660–6.PubMedGoogle Scholar
  52. 52.
    Gladman DD. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol. 1994;8(2):379–94.PubMedCrossRefGoogle Scholar
  53. 53.
    Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–21.PubMedCrossRefGoogle Scholar
  54. 54.
    Hsieh J, Kadavath S, Efthimiou P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol 2013 Nov 19Google Scholar
  55. 55.
    Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 2013 Mar 23Google Scholar
  56. 56.
    Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3(7):e2719.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.•
    Castelino M, Eyre S, Upton M, Ho P, Barton A. The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology (Oxford) 2013 Sep 24. First article describing the hypothetical relationship of specifically psoriatic arthritis with the (skin) microbiome.Google Scholar
  58. 58.
    Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337(6098):1115–9.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359–64.PubMedCrossRefGoogle Scholar
  60. 60.
    Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R569–80.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol 2013 Nov 17Google Scholar
  62. 62.
    Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Lindqvist U, Kristjansson G, Pihl-Lundin I, Hagforsen E, Michaelsson G. Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris. J Rheumatol. 2006;33(5):924–7.PubMedGoogle Scholar
  64. 64.
    Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27(5):1241–6.PubMedGoogle Scholar
  65. 65.
    Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011;13(5):409–15.PubMedCrossRefGoogle Scholar
  66. 66.
    Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol. 1995;22(4):680–3.PubMedGoogle Scholar
  67. 67.
    Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep. 2005;7(3):188–94.PubMedCrossRefGoogle Scholar
  68. 68.
    Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–34.PubMedCrossRefGoogle Scholar
  69. 69.
    Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26(5):644–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Arck P, Handjiski B, Hagen E, Pincus M, Bruenahl C, Bienenstock J, et al. Is there a 'gut-brain-skin axis'? Exp Dermatol. 2010;19(5):401–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72(7):1200–5.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Braun J. Therapy of spondyloarthritides. Adv Exp Med Biol. 2009;649:133–47.PubMedCrossRefGoogle Scholar
  74. 74.
    Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27–38.PubMedCrossRefGoogle Scholar
  75. 75.
    Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science. 2012;336(6086):1255–62.PubMedCrossRefGoogle Scholar
  76. 76.
    Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133–42.PubMedCrossRefGoogle Scholar
  77. 77.
    Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease–a nationwide, register-based finnish case-control study. Am J Epidemiol. 2012;175(8):775–84.PubMedCrossRefGoogle Scholar
  78. 78.
    Ceapa C, Wopereis H, Rezaiki L, Kleerebezem M, Knol J, Oozeer R. Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. Best Pract Res Clin Gastroenterol. 2013;27(1):139–55.PubMedCrossRefGoogle Scholar
  79. 79.
    Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin N Am. 2011;40(1):207–22.CrossRefGoogle Scholar
  80. 80.
    Hormannsperger G, von Schillde MA, Haller D. Lactocepin as a protective microbial structure in the context of IBD. Gut Microbes. 2013;4(2):152–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Madland TM, Bjorkkjaer T, Brunborg LA, Froyland L, Berstad A, Brun JG. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. J Rheumatol. 2006;33(2):307–10.PubMedGoogle Scholar
  82. 82.
    van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.PubMedCrossRefGoogle Scholar
  83. 83.
    Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107(10):1452–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6. e7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Hester Eppinga
    • 1
  • Sergey R. Konstantinov
    • 2
  • Maikel P. Peppelenbosch
    • 2
  • H. Bing Thio
    • 1
  1. 1.Department of DermatologyErasmus MC-University Medical Center RotterdamRotterdamThe Netherlands
  2. 2.Department of Gastroenterology and HepatologyErasmus MC-University Medical Center RotterdamRotterdamThe Netherlands

Personalised recommendations